Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

June 30, 2019

Conditions
Prostatic Neoplasms
Interventions
DRUG

cabazitaxel

25mg/m2 q3w

Trial Locations (1)

3075 EA

Erasmus MC Cancer Institute, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Erasmus Medical Center

OTHER